People: Covance Inc (CVD)
CVD on New York Consolidated
76.09USD
21 May 2013
76.09USD
21 May 2013
Price Change (% chg)
$-0.36 (-0.47%)
$-0.36 (-0.47%)
Prev Close
$77.33
$77.33
Open
$76.48
$76.48
Day's High
$76.69
$76.69
Day's Low
$75.50
$75.50
Volume
303,429
303,429
Avg. Vol
391,184
391,184
52-wk High
$78.36
$78.36
52-wk Low
$44.19
$44.19
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Joseph Herring |
57 | 2006 | Chairman of the Board, Chief Executive Officer |
Alison Cornell |
50 | 2012 | Chief Financial Officer, Vice President |
Richard Cimino |
53 | 2010 | Executive Vice President, Group President - Clinical Development |
Deborah Keller Tanner |
50 | 2010 | Executive Vice President, Group President - Research and Development Laboratories |
William Klitgaard |
59 | 2012 | Corporate Senior Vice President, Chief Information Officer, Treasurer |
James Lovett |
48 | 2003 | Corporate Senior Vice President, General Counsel, Secretary |
John Watson |
53 | 2010 | Corporate Senior Vice President, Chief Commercial Officer, President - Strategic Partnering |
Brian Nutt |
43 | 2011 | Principal Accounting Officer, Director - External Reporting |
Gary Costley |
69 | 2007 | Lead Independent Director |
Robert Barchi |
66 | 2003 | Independent Director |
Sandra Helton |
63 | 2003 | Independent Director |
John McCartney |
60 | 2009 | Independent Director |
Joseph Scodari |
60 | 2008 | Independent Director |
Bradley Sheares |
56 | 2009 | Independent Director |
Biographies
| Name | Description |
|---|---|
Joseph Herring |
Mr. Joseph L. Herring is Chairman of the Board, Chief Executive Officer of Covance Inc. He has been Covance's Chief Executive Officer since January 2005, and Chairman since January 2006. Mr. Herring was President and Chief Operating Officer from November 2001 to December 2004, and was Covance's Corporate Senior Vice President and President—Early Development Services from 1999 to November 2001. From September 1996 to September 1999, Mr. Herring was Corporate Vice President and General Manager of Covance Laboratories North America. Prior to joining Covance, Mr. Herring spent 18 years at the American Hospital Supply/Baxter International/Caremark International of healthcare service companies where he held of senior leadership positions, culminating in the position of Vice President and General Manager of its oncology business. |
Alison Cornell |
Ms. Alison Cornell is Chief Financial Officer, Vice President of Covance Inc. Ms. Cornell was Vice President, Global Financial Planning and Analysis from March 2009 to May 7, 2012. Ms. Cornell joined Covance in August 2004 as Vice President, Late Stage Development Services. Prior to joining Covance, Ms. Cornell spent 19 years at AT&T where she held a variety of senior leadership positions. Ms. Cornell has an MBA from Rutgers University, where she also attained her undergraduate degree. In addition, she is a Certified Treasury Professional (CTP) and completed the Program for Management Development at Harvard Business School. |
Richard Cimino |
Mr. Richard F. Cimino is Executive Vice President, Group President - Clinical Development of Covance Inc. From December 2004 through October 2010, Mr. Cimino was Corporate Senior Vice President and President—Clinical Development. Prior to that, Mr. Cimino was Covance's General Manager of Cardiac Safety Services commencing December 2003. Prior to that, Mr. Cimino was General Manager, America's Health Imaging Group and Corporate Vice President of Eastman Kodak Company. |
Deborah Keller Tanner |
Ms. Deborah L. Keller Tanner is Executive Vice President, Group President - Research and Development Laboratories of Covance Inc., November 2010. Ms. Keller Tanner was Corporate Senior Vice President and President—Global Central Laboratory Services from February 2006 through October 2010. Prior to that Ms. Keller Tanner was Covance's Global Vice President of Operations in Central Laboratory Services commencing in August 2001 and prior to that, Vice President—Analytical Services for Covance Laboratories—Europe. Ms. Keller Tanner has been with Covance for 25 years in positions of increasing responsibility. |
William Klitgaard |
Mr. William E. Klitgaard has been appointed as Corporate Senior Vice President, Chief Information Officer, Treasurer of Covance Inc. He has been appointed as Chief Information Officer of the Company, effective May 8, 2012. Prior to that, Mr. Klitgaard was Covance's Corporate Senior Vice President, Chief Financial Officer and Treasurer since September 2000. From September 1999 to September 2000, Mr. Klitgaard was Covance's Corporate Vice President, Strategy and Corporate Development and Treasurer. From October 1996 to September 1999, Mr. Klitgaard was Covance's Corporate Vice President and Treasurer. Prior to that, Mr. Klitgaard was Treasurer at Kenetech Corporation in San Francisco, before which, Mr. Klitgaard had spent eleven years in positions of increasing responsibility with Consolidated Freightways Inc. |
James Lovett |
Mr. James W. Lovett, Esq., is Corporate Senior Vice President, General Counsel, Secretary of Covance Inc. He has headed Covance's Nutritional Chemistry and Food Safety Services since January 2008 and has led Covance's Market Access Services since November 2010. From December 2001 to February 2003, Mr. Lovett was Corporate Vice President, General Counsel and Secretary of Covance. From 1997 to 2001, Mr. Lovett was with FMC Corporation in positions of increasing responsibility and, prior to that, was a partner in the law firm of McDermott, Will & Emery. |
John Watson |
Mr. John E. Watson is Corporate Senior Vice President, Chief Commercial Officer, President - Strategic Partnering of Covance Inc. Mr. Watson was Corporate Vice President and President—Strategic Partnering & Integrated Drug Development from January 2009 to November 2010. Prior to that, Mr. Watson was Covance's Vice President of Corporate Marketing & Sales. Mr. Watson has been with Covance in positions of increasing responsibility beginning in February 1999. Prior to joining Covance, Mr. Watson spent 12 years in roles of increasing responsibility within the Bristol-Myers Squibb companies. |
Brian Nutt |
Mr. Brian H. Nutt is Principal Accounting Officer, Director - External Reporting of Covance Inc. Mr. Nutt was Director, Corporate Finance from 2010 to 2011. Prior to that, Mr. Nutt was a Senior Manager, Corporate Finance. Prior to joining Covance in 2006, Mr. Nutt was Senior Director, Corporate Finance and Internal Audit for MedPointe Pharmaceuticals. |
Gary Costley |
Dr. Gary E. Costley, Ph.D., is Lead Independent Director of Covance Inc. He is a co-founder and managing director of C&G Capital and Management, LLC, which provides capital and management to health, medical and nutritional products and services companies. He was Chairman and Chief Executive Officer of International Multifoods Corporation, a manufacturer and marketer of branded consumer food and food service products from November 2001 until June 2004, and Chairman, President and Chief Executive Officer from 1997 through 2001. Dr. Costley is also a Director of The Principal Financial Group, a global financial institution, Tiffany & Co., a jewelry company, and Prestige Brand Holdings, Inc., a consumer products company. Dr. Costley has been a member of the Covance Board since September 2007. |
Robert Barchi |
Dr. Robert L. Barchi, M.D., Ph.D., is Independent Director of Covance Inc. He has been President of Rutgers University since September 2012. Prior to that, Dr. Barchi was President of Thomas Jefferson University commencing in September 2004. Prior to that, Dr. Barchi was Provost of the University of Pennsylvania since 1999. Previously, he served as Chair of the University of Pennsylvania's Department of Neurology and as founding Chair of the University's Department of Neuroscience. Dr. Barchi was also Director of the Mahoney Institute of Neurological Sciences for more than 12 years and was the Director of the Dana Fellowship Program in Neuroscience and Director of the Clinical Neuroscience Track. He was the founder and President of Penn Neurocare, a regional specialty network. Dr. Barchi has been a member of the Covance Board since October 2003. |
Sandra Helton |
Ms. Sandra L. Helton is Independent Director of Covance Inc. She was Executive Vice President and Chief Financial Officer of Telephone & Data Systems, Inc., a telecommunications service company, ("TDS") from October 2000 through December 2006. She joined TDS as Executive Vice President—Finance and Chief Financial Officer in August 1998. Prior to joining TDS, Ms. Helton was the Vice President and Corporate Controller of Compaq Computer Corporation between 1997 and 1998. Prior to that time, Ms. Helton was employed by Corning Incorporated. At Corning, Ms. Helton was Senior Vice President and Treasurer between 1994 and 1997 and was Vice President and Treasurer between 1991 and 1994. Ms. Helton is also a Director of The Principal Financial Group, a global financial institution, and Lexmark International, Inc., a printing and imaging solutions company. Ms. Helton has been a member of the Covance Board since September 2003. |
John McCartney |
Mr. John F. McCartney is Independent Director of Covance Inc. He has been Chairman of Huron Consulting Group Inc., a healthcare and educational consulting company since May 2010 and a director since October 2004. Mr. McCartney served as Chairman of A.M. Castle & Co., a specialty metals and plastics distributor from May 2007 to May 2010 and remains on its Board of Directors. Mr. McCartney serves as the Chairman of Westcon Group, Inc., a specialty distributor of networking and communications equipment since March 2011 and has served on its Board of Directors since 1998. Mr. McCartney was the Vice-Chairman of Datatec Limited, a technology holding company, from 1998 to 2004, and currently serves on its Board of Directors. Mr. McCartney was formerly President and Chief Operating Officer of U.S. Robotics. Mr. McCartney also served on the Board of Federal Signal Corporation, an environmental, safety and transportation solutions company, until April 2010. Mr. McCartney has been a member of the Covance Board since May 2009. |
Joseph Scodari |
Mr. Joseph C. Scodari is Independent Director of Covance Inc. He was Worldwide Chairman, Pharmaceuticals Group, of Johnson & Johnson, a diversified healthcare company, ("J&J") and a member of J&J's Executive Committee from March 2005 until March 2008. From 2003 to March 2005, Mr. Scodari was Company Group Chairman of J&J's Biopharmaceutical Business. Mr. Scodari joined J&J in 1999 as President and Chief Operating Officer of Centocor Inc., when J&J acquired the company. Mr. Scodari was a Director of Actelion Pharmaceuticals, Ltd., a pharmaceuticals company until May 2011. Mr. Scodari is a Director of Endo Health Solutions, Inc., a diversified healthcare company. Mr. Scodari has been a member of the Covance Board since May 2008. |
Bradley Sheares |
Dr. Bradley T. Sheares, Ph.D., is Independent Director of Covance Inc. He served as Chief Executive Officer of Reliant Pharmaceuticals, Inc., a pharmaceutical company with integrated sales, marketing and development experience that marketed a portfolio of branded cardiovascular pharmaceutical products, from January 2007 through its acquisition by GlaxoSmithKline plc in December 2007. Prior to joining Reliant, Dr. Sheares served as President of U.S. Human Health, Merck & Co., Inc. from March 2001 until July 2006. Prior to that time, he served as Vice President, Hospital Marketing and Sales for Merck's U.S. Human Health business. Dr. Sheares joined Merck in 1987 as a research fellow in the Merck Research Laboratories and held a wide range of positions within Merck, in business development, sales, and marketing, before becoming Vice President in 1996. Dr. Sheares is also a Director of The Progressive Corporation, an insurance and related services company, Honeywell International, Inc., a diversified technology and manufacturing company, and Henry Schein, Inc., a healthcare products and services company. Dr. Sheares was a director of IMS Health, a healthcare services company, until February 2010. Dr. Sheares has been a member of the Covance Board since February 2009. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Joseph Herring |
7,931,070 |
Alison Cornell |
902,330 |
Richard Cimino |
1,743,080 |
Deborah Keller Tanner |
1,439,860 |
William Klitgaard |
1,941,140 |
James Lovett |
1,616,250 |
John Watson |
2,341,190 |
Brian Nutt |
-- |
Gary Costley |
-- |
Robert Barchi |
-- |
Sandra Helton |
-- |
John McCartney |
-- |
Joseph Scodari |
-- |
Bradley Sheares |
-- |
As Of 30 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
Joseph Herring |
326,876 | 8,246,195 |
Alison Cornell |
0 | 0 |
Richard Cimino |
12,000 | 147,468 |
Deborah Keller Tanner |
3,700 | 96,176 |
William Klitgaard |
133,130 | 3,067,712 |
James Lovett |
56,552 | 1,227,343 |
John Watson |
0 | 0 |
Brian Nutt |
0 | 0 |
Gary Costley |
0 | 0 |
Robert Barchi |
0 | 0 |
Sandra Helton |
0 | 0 |
John McCartney |
0 | 0 |
Joseph Scodari |
0 | 0 |
Bradley Sheares |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
LOVETT JAMES W |
10,259 | $77.00 |
LOVETT JAMES W |
330 | $0.00 |
HELTON SANDRA LYNN |
652 | $74.27 |
MCCARTNEY JOHN F |
1,367 | $0.00 |
SCODARI JOSEPH C |
1,367 | $0.00 |
HELTON SANDRA LYNN |
1,367 | $0.00 |
COSTLEY GARY E |
1,367 | $0.00 |
SHEARES BRADLEY T |
1,367 | $0.00 |
BARCHI ROBERT |
1,367 | $0.00 |
NUTT BRIAN H |
1,250 | $39.80 |
NUTT BRIAN H |
1,250 | $72.50 |
NUTT BRIAN H |
25 | $67.78 |
CORNELL ALISON A |
168 | $67.78 |
KLITGAARD WILLIAM E |
10,463 | $0.00 |
CORNELL ALISON A |
19,300 | $0.00 |
LOVETT JAMES W |
11,131 | $0.00 |
WATSON JOHN E |
125 | $69.01 |
CIMINO RICHARD F |
9,811 | $0.00 |
CIMINO RICHARD F |
145 | $69.01 |
WATSON JOHN E |
9,773 | $0.00 |
HERRING JOSEPH L |
75,728 | $0.00 |
TANNER DEBORAH L |
152 | $69.01 |
NUTT BRIAN H |
831 | $0.00 |
HERRING JOSEPH L |
1,213 | $69.01 |
NUTT BRIAN H |
85 | $69.01 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
